Business
Media
Conferences
Publications
CME/CE
Resources
Subscribe

Opinion|Videos|August 6, 2024

Therapies Beyond BCG: FDA-Approved and Emerging Options

Author(s)Trinity Bivalacqua, MD, PhD, Mark D. Tyson, MD, MPH

Experts discuss available therapies beyond BCG.

Episodes in this series

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 3 Recurrence and BCG Resistance in High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 4 Therapies Beyond BCG: FDA-Approved and Emerging Options

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 5 Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 6 CORE-001 Trial Participation and Eligibility Criteria

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 7 Comparing Cretostimogene and BCG Administration Methods

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 8 Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 9 Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 10 Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 11 Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 12 Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following question:

For patients who are either unable to receive BCG therapy, or BCG unresponsive, what other therapeutic options are currently available?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Laura Bukavina, MD, discusses debate on high-grade tumor risk stratification

ByLaura Bukavina, MD, MPH, MSc

December 13th 2025

EMA recommends conditional approval of Anktiva in BCG-unresponsive NMIBC

ByHannah Clarke

December 12th 2025

Fed Ghali, MD on key unanswered questions with perioperative EV/pembro

ByFed Ghali, MD

December 11th 2025

2025 year in review: Breakthroughs in urologic oncology during a year of unprecedented awareness

ByMichael S. Cookson, MD, MMHC, FACS

December 10th 2025

Gal Wald, MD on PROs from phase 2 gemcitabine + BCG trial in NMIBC

December 10th 2025

Latest CME

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Wisconsin

Scott T. Tagawa, MD, MS, FACP, FASCO; Kate Baxstrom, MD

DSUI Urology on the Beach

In-Person Event

DSUI Urology on the Beach

January 16-18, 2026

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Glenn M. Chertow, MD, MPH; Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Preethi Yerram, MD

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Developing a Long-Term Monitoring Plan to Assess Prostate Cancer Risk

Jason M. Hafron, MD

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Guiding Prostate Cancer Diagnosis with Biomarker Testing

Aaron D. Berger, MD

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Burst CME™: Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis

Stacy Loeb, MD, MSc, PhD (Hon)

Trending on Urology Times

Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men

Sildenafil cream for female sexual arousal disorder available to prescribe in select states

Experts urge FDA to revisit labeling for testosterone replacement therapy in men

FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC

FDA approves zoliflodacin for uncomplicated urogenital gonorrhea

© 2025 MJH Life Sciences^®

All rights reserved.